APOBEC3 inhibition of mouse mammary tumor virus infection: The role of cytidine deamination versus inhibition of reverse transcription

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 4808-4817

  MacMillan, Alyssa L ^a   Kohli, Rahul M ^a   Ross, Susan R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B EDITING COMPLEX 3 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; APOLIPOPROTEIN B EDITING COMPLEX 3 GENE; ARTICLE; CONTROLLED STUDY; DEAMINATION; ENZYME SPECIFICITY; FEMALE; GENE; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION; VIRION; VIRUS CORE;

ANIMALS; CYTIDINE; CYTIDINE DEAMINASE; DEAMINATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MALE; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETROVIRIDAE INFECTIONS; REVERSE TRANSCRIPTION; TUMOR VIRUS INFECTIONS; VIRUS ASSEMBLY;

MOUSE MAMMARY TUMOR VIRUS; MURINAE; MUS;

EID: 84876329767     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00112-13     Document Type: Article

References (59)

1. Emerman M, Malik HS. 2010. Paleovirology-modern consequences of ancient viruses. PLoS Biol. 8:e1000301. doi:10.1371/journal.pbio.1000301.
2. Malim MH, Bieniasz PD. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2:a006940. doi:10.1101 /cshperspect.a006940.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
4. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jonsson SR, Landau NR, Lochelt M, Malik HS, Malim MH, Munk C, O'Brien SJ, Pathak VK, Strebel K, Wain- Hobson S, Yu XF, Yuhki N, Harris RS. 2009. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83:494-497.
5. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
6. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458.
7. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
8. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073- 6076.
9. Goila-Gaur R, Strebel K. 2008. HIV-1, APOBEC, and intrinsic immunity. Retrovirology 5:51.
10. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. 2004. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337:585-596.
11. Langlois MA, Beale RC, Conticello SG, Neuberger MS. 2005. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33:1913-1923.
12. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166 -170.
13. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80: 8450-8458.
14. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096 -7108.
15. Li XY, Guo F, Zhang L, Kleiman L, Cen S. 2007. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282:32065-32074.
16. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L. 2007. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81: 11322-11331.
17. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595.
18. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118 -128.
19. Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu XF. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81:7238 -7248.
20. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e1000231. doi:10.1371/journal.ppat.1000231.
21. Schumacher AJ, Haché G, MacDuff DA, Brown WL, Harris RS. 2008. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD and HIV-1 restriction. J. Virol. 82:2652-2660.
22. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K. 2007. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81:13346 -13353.
23. + T cells is associated with the inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 87:1508- 1517.
24. Nandi S, McGrath CM. 1973. Mammary neoplasia in mice. Adv. Cancer Res. 17:353- 414.
25. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445:927-930.
26. Rulli SJ, Jr, Mirro J, Hill SA, Lloyd P, Gorelick RJ, Coffin JM, Derse D, Rein A. 2008. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J. Virol. 82:6566-6575.
27. Browne EP, Littman DR. 2008. Species-specific restriction of Apobec3- mediated hypermutation. J. Virol. 82:1305-1313.
28. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M. 2008. Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82:10998- 11008.
29. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM, Ross SR, Fan H. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385:455- 463.
30. Langlois MA, Kemmerich K, Rada C, Neuberger MS. 2009. The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J. Virol. 83:11550 -11559.
31. Okeoma CM, Petersen J, Ross SR. 2009. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection J. Virol. 83:3029 -3038.
32. Miyazawa M, Tsuji-Kawahara S, Kanari Y. 2008. Host genetic factors that control immune responses to retrovirus infections. Vaccine 26:2981- 2996.
33. Sanville B, Dolan MA, Wollenberg K, Yan Y, Martin C, Yeung ML, Strebel K, Buckler-White A, Kozak CA. 2010. Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog. 6:e1000974. doi: 10.1371/journal.ppat.1000974.
34. Li J, Hakata Y, Takeda E, Liu Q, Iwatani Y, Kozak CA, Miyazawa M. 2012. Two genetic determinants acquired late in mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency. PLoS Pathog. 8:e1002478. doi:10.1371/journal.ppat.1002478.
35. Golovkina TV, Chervonsky A, Dudley JP, Ross SR. 1992. Transgenic mouse mammary tumor virus superantigen expression prevents viral infection. Cell 69:637- 645.
36. Zhang Y, Rassa JC, deObaldia EM, Albritton L, Ross SR. 2003. Identification of the mouse mammary tumor virus envelope receptor-binding domain. J. Virol. 77:10468 -10478.
37. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR. 2010. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8:534 -543.
38. Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. 2012. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 8:751-758.
39. Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT. 2009. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 284:22898 -22904.
40. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM. 2008. Vpr.A3A chimera inhibits HIV replication. J. Biol. Chem. 283:2518 -2525.
41. Petit V, Guetard D, Renard M, Keriel A, Sitbon M, Wain-Hobson S, Vartanian JP. 2009. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J. Mol. Biol. 385:65-78.
42. Russell RA, Moore MD, Hu WS, Pathak VK. 2009. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6:16.
43. Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, Gerstoft J, Fugger L, McMichael A, Rambaut A, Iversen AK. 2012. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet. 8:e1002550. doi:10.1371/journal.pgen.1002550.
44. Vetter ML, D'Aquila RT. 2009. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells. J. Virol. 83:8646-8654.
45. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimarelli A. 2011. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 7:e1002221. doi:10.1371/journal.ppat.1002221.
46. Koning FA, Goujon C, Bauby H, Malim MH. 2011. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J. Virol. 85:13448 -13452.
47. Okeoma CM, Low A, Bailis W, Fan HY, Peterlin BM, Ross SR. 2009. Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J. Virol. 83:3486 -3495.
48. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321:1343-1346.
49. + T cells. J. Virol. 75:7973-7986.
50. + T cells in vivo. J. Virol. 79:1975-1980.
51. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. 2006. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80:9259 -9269.
52. Renard M, Henry M, Guetard D, Vartanian JP, Wain-Hobson S. 2010. APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo. J. Mol. Biol. 400:323-334.
53. Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, McMahon MA, Siliciano RF, Gearhart PJ, Stivers JT. 2010. Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J. Biol. Chem. 285:40956- 40964.
54. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. 2008. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 82:3125- 3130.
55. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA. 2008. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82:8172- 8182.
56. Hulme AE, Perez O, Hope TJ. 2011. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 108:9975-9980.
57. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C, Diaz-Griffero F. 2012. RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J. Virol. 86:1717-1727.
58. Abudu A, Takaori-Kondo A, Izumi T, Shirakawa K, Kobayashi M, Sasada A, Fukunaga K, Uchiyama T. 2006. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16:1565-1570.
59. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC. 2010. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J. Immunol. 185:1114 -1123.